Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
Four offers and a call from Bourla: How Pfizer narrowly beat out rival bidder to swallow GBT and its sickle cell drugs for $5.4B
Pfizer wasn’t the first — or only — company that wanted to buy Global Blood Therapeutics.
In fact, Pfizer elbowed a rival bidder …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
